Authors:
Sofia Maraki Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece

Search for other papers by Sofia Maraki in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0003-0945-1732
,
Viktoria Eirini Mavromanolaki University of Crete Medical School, Heraklion, Crete, Greece

Search for other papers by Viktoria Eirini Mavromanolaki in
Current site
Google Scholar
PubMed
Close
,
Anna Kasimati Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece

Search for other papers by Anna Kasimati in
Current site
Google Scholar
PubMed
Close
,
Dimitra Stafylaki Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece

Search for other papers by Dimitra Stafylaki in
Current site
Google Scholar
PubMed
Close
, and
Effie Scoulica Laboratory of Clinical Microbiology and Molecular Microbiology, School of Medicine, University of Crete, Crete, Greece

Search for other papers by Effie Scoulica in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract

Nocardiosis is a rare disease affecting both immunocompromised and immunocompetent hosts, presented in various clinical forms ranging from localized to disseminated infection. Aim of the present study was to investigate the clinical and microbiological characteristics of nocardiosis, antimicrobial resistance profiles, treatment, and outcomes of Nocardia infection over the last 5 years at our institution. The medical records and microbiological data of patients affected by nocardiosis and treated at the university hospital of Heraklion, Crete, Greece, between 2018 and 2022, were retrospectively analyzed. The isolates were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and through sequencing of 16S rRNA. Antimicrobial susceptibility for 17 agents was determined by E-test and results were interpreted according to CLSI guidelines. Among the 28 Nocardia isolates, eight species were identified, with Nocardia brasiliensis being the most prevalent (32.1%), followed by Nocardia otitidiscaviarum (25%), and Nocardia farcinica (14.3%). Skin and soft tissue infections were the most common presentations, noted in 13 (50%) patients, followed by pulmonary infection presented in 10 (38.5%) patients. Fifteen patients (57.7%) had at least one underlying disease, and 11 (42.3%) were on immunosuppressive or long-term corticosteroid treatment. Susceptibility rates of linezolid, tigecycline, amikacin, trimethoprim-sulfamethoxazole, moxifloxacin, and imipenem were 100, 100, 96.4, 92.9, 82.1, and 42.9%, respectively. The 26 patients in this study were treated with various antibiotics. Mortality rate was 3.8%, and the patient who died had disseminated infection. Since epidemiology and antimicrobial susceptibility are evolving, continuous surveillance is mandatory in order to initiate appropriate treatment in a timely manner.

  • 1.

    Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006; 19: 259282.

    • Search Google Scholar
    • Export Citation
  • 2.

    Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc 2012; 87: 403407.

  • 3.

    Coussement J, Lebeaux D, van Delden C, Guillot H, Freund R, Marbus S, et al. Nocardia infection in solid organ transplant recipients: a multicenter European case-control study. Clin Infect Dis 2016; 63: 338345.

    • Search Google Scholar
    • Export Citation
  • 4.

    Palomba E, Liparoti A, Tonizzo A, Castelli V, Alagna L, Bozzi G, et al. Nocardia infections in the immunocompromised host: a case series and literature review. Microorganisms 2022; 10: 1120.

    • Search Google Scholar
    • Export Citation
  • 5.

    Steinbrink J, Leavens J, Kauffman CA, Miceli MH. Manifestations and outcomes of Nocardia infections: comparison of immunocompromised and nonimmunocompromised adult patients. Medicine (Baltimore) 2018; 97: e12436.

    • Search Google Scholar
    • Export Citation
  • 6.

    Marques C, Ribeiro M, Bonccoraglio MT, Braga J, Pereira AF, Ogando A. Disseminated nocardiosis: the complexity of the diagnosis. J Med Cases 2021; 12: 205208.

    • Search Google Scholar
    • Export Citation
  • 7.

    Margalit I, Muhsen K, Ben Ari Y, Ben-Zvi H, Shostak Y, Krause I, et al. Nocardia colonization in contrast to nocardiosis: a comparison of patients' clinical characteristics. Eur J Clin Microbiol Infect Dis 2020; 39: 759763.

    • Search Google Scholar
    • Export Citation
  • 8.

    Al Akhrass F, Hachem R, Mohamed JA, Tarrand J, Kontoyiannis DP, Chandra J, et al. Central venous catheter-associated Nocardia bacteremia in cancer patients. Emerg Infect Dis 2011; 17: 16511658.

    • Search Google Scholar
    • Export Citation
  • 9.

    Vuotto F, Faure K, Queyre V, Dessein R, Pasquet A, Lambert M, et al. Vascular nosocomial Nocardia farcinica infection after arterial stenting in an immunocompetent patient. Can J Infect Dis Med Microbiol 2011; 22: e10e11.

    • Search Google Scholar
    • Export Citation
  • 10.

    Exmelin L, Malbruny B, Vergnaud M, Prosvost F, Boiron P, Morel C. Molecular study of nosocomial nocardiosis outbreak involving heart transplant recipients. J Clin Microbiol 1996; 34: 10141016.

    • Search Google Scholar
    • Export Citation
  • 11.

    Wenger PN, Brown JM, McNeil MM, Jarvis WR. Nocardia farcinica sternotomy site infections in patients following open heart surgery. J Infect Dis 1998; 178: 15391543.

    • Search Google Scholar
    • Export Citation
  • 12.

    Kachi S, Okazaki M, Takeda H, Igarashi H, Kobayashi O, Watanabe H, et al. Outbreak of Nocardia farcinica infection with the same pattern in randomly amplified polymo-rphic DNA analysis. J Hosp Infect 2006; 62: 502506.

    • Search Google Scholar
    • Export Citation
  • 13.

    Maraki S, Mavromanolaki VE, Detorakis EE, Stafylaki D, Moraitis P, Scoulica E. Nocardia elegans primary iliopsoas abscess: a case report and literature review. Acta Microbiol Immunol Hung 2022; 69: 351357.

    • Search Google Scholar
    • Export Citation
  • 14.

    Mylona E, Papastamopoulos V, Giannopoulou M, Perivolioti E, Psaroudaki Z, Skoutelis A. Lymphocutaneous nocardiosis in a kidney transplant patient successfully treated with tigecycline. Saudi J Kidney Dis Transpl 2018; 29: 12071210.

    • Search Google Scholar
    • Export Citation
  • 15.

    Maraki S, Scoulica E, Nioti E, Tselentis Y. Nocardial infection in Crete, Greece: review of fifteen cases from 2003 to 2007. Scand J Infect Dis 2009; 41: 122127.

    • Search Google Scholar
    • Export Citation
  • 16.

    Glupczynski Y, Berhin C, Janssens M, Wauters G. Determination of antimicrobial susceptibility patterns of Nocardia spp. from clinical specimens by Etest. Clin Microbiol Infect 2006; 12: 905912.

    • Search Google Scholar
    • Export Citation
  • 17.

    Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing of mycobacteria, Nocardia spp. and other aerobic actinomycetes- 2 nd ed.:; approved standard M24S. 2023. Wayne, PA: CLSI. Wayne, PA: CLSI.

    • Search Google Scholar
    • Export Citation
  • 18.

    Woodworth MH, Saullo JL, Lantos PM, Cox GM, Stout JE. Increasing Nocardia incidence associated with bronchiectasis at a tertiary care center. Ann Am Thorac Soc 2017; 14: 347354.

    • Search Google Scholar
    • Export Citation
  • 19.

    Yang J, Ren HT, Wang J, Dong AY, Chen YL, Hu DX, et al. Clinical characteristics, susceptibility profiles, and treatment of nocardiosis: a multicenter retrospective study in 2015–2021. Int J Infect Dis 2023; 130: 136143.

    • Search Google Scholar
    • Export Citation
  • 20.

    Pintado V, Gomez-Mampaso E, Fortun J, Meseguer MA, Cobo J, Navas E, et al. Infection with Nocardia species: clinical spectrum of disease and species distribution in Madrid, Spain, 1978–2001. Infection 2002; 30: 338340.

    • Search Google Scholar
    • Export Citation
  • 21.

    Torres HA, Reddy BT, Raad II, Tarrand J, Bodey GP, Hanna HA, et al. Nocardiosis in cancer patients. Medicine (Baltimore) 2002; 81: 388397.

    • Search Google Scholar
    • Export Citation
  • 22.

    Cattaneo C, Antoniazzi F, Caira M, Castagnola C, Delia M, Tumbarello M, et al. Nocardia spp infections among hematological patients: results of a retrospective multicenter study. Int J Infect Dis 2013; 17: e610e614.

    • Search Google Scholar
    • Export Citation
  • 23.

    Martínez Tomás R, Menéndez Villanueva R, Reyes Calzada S, Santos Durantez M, Vallés Tarazona JM, Modesto Alapont M, et al. Pulmonary nocardiosis: risk factors and outcomes. Respirology 2007; 12: 394400.

    • Search Google Scholar
    • Export Citation
  • 24.

    Colaneri M, Lombardi A, Morea A, Monzillo V, Mariani B, Marone M, et al. An eight-year experience of Nocardia infection in Italy: does immunosuppression matter? New Microbiol 2021; 44: 111116.

    • Search Google Scholar
    • Export Citation
  • 25.

    Fujita T, Ikari J, Watanabe A, Tatsumi K. Clinical characteristics of pulmonary nocardiosis in immunocompetent patients. J Infect Chemother 2016; 22: 738743.

    • Search Google Scholar
    • Export Citation
  • 26.

    Yang CH, Kuo SF, Chen FJ, Lee CH. Clinical manifestations and outcome of nocardiosis and antimicrobial susceptibility of Nocardia species in southern Taiwan, 2011–2021. J Microbiol Immunol Infect 2023; 56: 382391.

    • Search Google Scholar
    • Export Citation
  • 27.

    Cordioli G, Di Pietra G, Asaad S, Meneghello S, Del Vecchio C, De Canale E, et al. Nocardia infections in Italy: from a local to a national view. New Microbiol 2023; 46: 6874.

    • Search Google Scholar
    • Export Citation
  • 28.

    Lebeaux D, Bergeron E, Berthet J, Djadi-Prat J, Mouniée D, Boiron P, et al. Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010–2015. Clin Microbiol Infect 2019; 25: 489495.

    • Search Google Scholar
    • Export Citation
  • 29.

    Averbuch D, De Greef J, Duréault A, Wendel L, Tridello G, Lebeaux D, et al. Nocardia infections in hematopoietic cell transplant recipients: a multicenter international retrospective study of the infectious diseases working party of the European Society for Blood and Marrow Transplantation. Clin Infect Dis 2022; 75: 8897.

    • Search Google Scholar
    • Export Citation
  • 30.

    Galar A, Martín-Rabadán P, Marín M, Cercenado E, Sánchez-Carrillo C, Valerio M, et al. Revisiting nocardiosis at a tertiary care institution: any change in recent years? Int J Infect Dis 2021; 102: 446454.

    • Search Google Scholar
    • Export Citation
  • 31.

    Hamdi AM, Fida M, Deml SM, Abu Saleh OM, Wengenack NL. Retrospective analysis of antimicrobial susceptibility profiles of Nocardia species from a tertiary hospital and reference laboratory, 2011 to 2017. Antimicrob Agents Chemother 2020; 64: e01868–19.

    • Search Google Scholar
    • Export Citation
  • 32.

    Sundac L, Dang L, Ho J, Hanson J, Smith S, Choong K, et al. A multi-centre retrospective study of Nocardia speciation and antimicrobial susceptibility in Queensland, Australia. Eur J Clin Microbiol Infect Dis 2023; 42: 339345.

    • Search Google Scholar
    • Export Citation
  • 33.

    Wang H, Zhu Y, Cui Q, Wu W, Li G, Chen D, et al. Epidemiology and antimicrobial resistance profiles of the Nocardia species in China, 2009 to 2021. Microbiol Spectr 2022; 10: e0156021.

    • Search Google Scholar
    • Export Citation
  • 34.

    Williams E, Jenney AW, Spelman DW. Nocardia bacteremia: a single-center retrospective review and a systematic review of the literature. Int J Infect Dis 2020; 92: 197207.

    • Search Google Scholar
    • Export Citation
  • 35.

    Yang M, Xu M, Wei W, Gao H, Zhang X, Zhao H, et al. Clinical findings of 40 patients with nocardiosis: a retrospective analysis in a tertiary hospital. Exp Ther Med 2014; 8: 2530.

    • Search Google Scholar
    • Export Citation
  • 36.

    Khot PD, Bird BA, Durrant RJ, Fisher MA. Identification of Nocardia species by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2015; 53: 33663369.

    • Search Google Scholar
    • Export Citation
  • 37.

    Hodille E, Prudhomme C, Dumitrescu O, Benito Y, Dauwalder O, Lina G. Rapid, easy, and reliable identification of Nocardia sp. by MALDI-TOF Mass Spectrometry, VITEK®-MS IVD V3.2 database, using direct deposit. Int J Mol Sci 2023; 24: 5469.

    • Search Google Scholar
    • Export Citation
  • 38.

    Durand T, Vautrin F, Bergeron E, Girard V, Polsinelli S, Monnin V, et al. Assessment of VITEK® MS IVD database V3.0 for identification of Nocardia spp. using two culture media and comparing direct smear and protein extraction procedures. Eur J Clin Microbiol Infect Dis 2020; 39: 559567.

    • Search Google Scholar
    • Export Citation
  • 39.

    Kishor K, Dhasmana N, Kamble SS, Sahu RK. Linezolid induced adverse drug reactions - an update. Curr Drug Metab 2015; 16: 553559.

  • 40.

    Traxler RM, Bell ME, Lasker B, Headd B, Shieh WJ, McQuiston JR. Updated review on Nocardia species: 2006–2021. Clin Microbiol Rev 2022; 35: e0002721.

    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand
The author instructions are available in PDF.
Please, download the file from HERE

 

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • CABELLS Journalytics
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded

2023  
Web of Science  
Journal Impact Factor 1.3
Rank by Impact Factor Q4 (Immunology)
Journal Citation Indicator 0.31
Scopus  
CiteScore 2.3
CiteScore rank Q3 (Infectious Diseases)
SNIP 0.389
Scimago  
SJR index 0.308
SJR Q rank Q3

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2025 Online subsscription: 772 EUR / 848 USD
Print + online subscription: 860 EUR / 944 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Feb 2024 80 3 5
Mar 2024 146 1 1
Apr 2024 138 0 0
May 2024 76 0 0
Jun 2024 71 0 1
Jul 2024 55 0 0
Aug 2024 0 0 0